Lucknow News Flash

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Multiple Myeloma Overview

Multiple Myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma.The plasma cells make an abnormal protein known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. 

Some of the key facts of the Multiple Myeloma Market Report:

• Multiple Myeloma market size is anticipated to increase with a significant CAGR during the study period 2019-32.
• The total incident case of Multiple Myeloma was 70,000+cases in the 7MM in the year 2020.
• Multiple Myeloma epidemiology based on gender analyzed that Multiple Myeloma diagnosis is more prevalent in males as compared to females.
• People in the age group 65-74 are most likely to get diagnosed with Multiple Myeloma.
• Multiple Myeloma key companies such as AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and others are working towards developing the Multiple Myeloma drugs.
• Multiple Myeloma emerging therapies like Venetoclax, ABBV 383, Teclistamab, Talquetamab, REGN5458, Iberdomide, Descartes-11 are working towards developing the Multiple Myeloma drugs.

Request a sample for the Multiple Myeloma Market Report

Key benefits of the Multiple Myeloma Market report:

1. Multiple Myeloma market report covers a descriptive overview and comprehensive insight of the Multiple Myeloma Epidemiology and Multiple Myeloma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Multiple Myeloma market report provides insights on the current and emerging therapies.
3. Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Multiple Myeloma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Multiple Myeloma market.

The Report Covers the Multiple Myeloma Epidemiology, Segmented by –

• Total Incident Cases of Multiple Myeloma in the 7MM (2019–2032)
• Gender-specific Cases of Multiple Myeloma in the 7MM (2019–2032)
• Age-specific Cases of Multiple Myeloma in the 7MM (2019–2032)
• Mutation-specific Cases of Multiple Myeloma in the 7MM (2019–2032)
• Treated Cases of Multiple Myeloma by the line of therapies in the 7MM (2019–2032)
• Treated Cases of Multiple Myeloma by status in the 7MM (2019–2032)

Multiple Myeloma Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Multiple Myeloma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Multiple Myeloma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to be launched during the study period. The analysis covers the Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Multiple Myeloma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Myeloma Market Drivers

• Increasing Multiple Myeloma incidence
• High adoption rate of newer Multiple Myeloma therapies
• Increase in the geriatric population

Multiple Myeloma Market Barriers

• Expensive Multiple Myeloma treatment options
• Toxicities and adverse events of various Multiple Myeloma therapeutics

Learn more by requesting for sample @ Multiple Myeloma Market Landscape 

Multiple Myeloma Pipeline Therapies and Key Companies 

• Descartes-11: Cartesian Therapeutics
• Iberdomide: Bristol-Myers Squibb/Celgene
• REGN5458: Regeneron Pharmaceuticals
• Talquetamab: Janssen Pharmaceuticals
• Teclistamab: Janssen Pharmaceuticals
• ABBV 383: AbbVie
• Venetoclax: AbbVie and Roche

Table of Contents

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma 

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2019–2032)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market drivers

16. Multiple Myeloma Market barriers

17.  Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Multiple Myeloma Pipeline 

“Multiple Myeloma Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple Myeloma market. A detailed picture of the Multiple Myeloma pipeline landscape is provided, which includes the disease overview and Multiple Myeloma treatment guidelines.

Multiple Myeloma Epidemiology

DelveInsight’s ‘Multiple Myeloma Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com